Filed Pursuant to Rule 424(b)(2)
Registration No. 333-279084
Prospectus Supplement to Prospectus dated May 2, 2024
Becton, Dickinson and Company
€1,000,000,000 3.828% Notes due 2032
We are offering €1,000,000,000 aggregate principal amount of 3.828% Notes due 2032 (the “notes”). Interest on the notes will be payable in cash annually in arrears on of each year, beginning on June 7, 2025. The notes will mature on June 7, 2032.
We may, at our option, redeem the notes, in whole or in part, at any time and from time to time, at the applicable redemption prices described in this prospectus supplement. See “Description of Notes—Optional Redemption.” In addition, we may redeem the notes in whole, but not in part, at any time in the event of certain developments affecting U.S. taxation. See “Description of Notes—Redemption for Tax Reasons.” If a change of control triggering event occurs as described in this prospectus supplement under the heading “Description of Notes—Offer to Repurchase Upon Change of Control Triggering Event,” unless we have exercised our right to redeem such notes as described under “Description of Notes—Optional Redemption” or “Description of Notes—Redemption for Tax Reasons,”we will be required to offer to purchase the notes from the holders.
Concurrently with this offering, we are offering $600,000,000 aggregate principal amount of our 5.081% Notes due 2029 and Becton Dickinson Euro Finance S.à r.l., which is our indirect, wholly-owned finance subsidiary (“BD Finance”), is offering €800,000,000 aggregate principal amount of its 4.029% Notes due 2036, which notes are fully and unconditionally guaranteed on a senior unsecured basis by us (the “concurrent offerings”). The closings of this offering and the concurrent offerings are not conditioned on each other. The concurrent offerings are being made by means of separate prospectus supplements and not by means of this prospectus supplement. This prospectus supplement is not an offer to sell or a solicitation of an offer to buy any securities being offered in the concurrent offerings. See “Use of Proceeds.”
We expect to use the net proceeds from this offering, together with proceeds from the concurrent offerings, borrowings under our commercial paper program and cash on hand, (i) to fund the cash consideration payable by us for the acquisition (the “Acquisition”) of the Critical Care business (the “Business”) of Edwards Lifesciences Corporation (“Seller Parent”) and its subsidiaries by us and/or certain of our subsidiaries, (ii) to pay fees and expenses in respect of the foregoing, and (iii) for general corporate purposes. This offering is not conditioned upon the consummation of the Acquisition, which, if completed, will occur subsequent to the closing of this offering, and we cannot assure you that the Acquisition will be consummated on the terms described herein, or at all. See “Summary—Recent Developments—The Acquisition” and “Use of Proceeds.”
The notes will be our senior unsecured obligations and will rank equally in right of payment with all of our other senior unsecured indebtedness, including our other outstanding senior notes. The notes will be issued in minimum denominations of €100,000 and in integral multiples of €1,000 in excess thereof.
The notes constitute a new issue of securities for which there is no established trading market. We intend to apply to list the notes on the New York Stock Exchange (“NYSE”). The listing application will be subject to approval by the NYSE. We expect trading in the notes on the NYSE to begin within 30 days after the original issue date of the notes.
Investing in the notes involves risks that are described in the “Risk Factors” section of this prospectus supplement beginning on page S-
6 and in our latest Annual Report on Form 10-K, which is incorporated by reference into this prospectus supplement (as such risk factors may be updated from time to time in our public filings).
Neither the Securities and Exchange Commission (the “SEC”) nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the related prospectus. Any representation to the contrary is a criminal offense.
Notes
|
|
|
100.000% |
|
|
€1,000,000,000 |
|
|
0.400% |
|
|
€4,000,000 |
|
|
99.600% |
|
|
€996,000,000 |
(1)
|
Plus accrued interest from June 7, 2024, if settlement occurs after that date. |
The underwriters expect to deliver the notes to purchasers in book-entry form through the facilities of Euroclear Bank SA/NV (“Euroclear”) and Clearstream Banking S.A. (“Clearstream”), against payment on or about June 7, 2024.
Joint Book-Running Managers
Citigroup |
|
|
Barclays |
|
|
BNP PARIBAS |
|
|
J.P. Morgan |
|
|
Wells Fargo
Securities
|
MUFG |
|
|
Scotiabank |
|
|
US Bancorp |
Co-Managers
Academy Securities |
|
|
ING |
|
|
IMI – Intesa Sanpaolo |
|
|
Loop Capital Markets |
|
|
|
|
|
|
|
|
|
|
R. Seelaus & Co., LLC |
|
|
Siebert Williams Shank |
|
|
Standard Chartered Bank |
|
|
TD Securities |
The date of this prospectus supplement is June 4, 2024.